vs
ASSURED GUARANTY LTD（AGO）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
ASSURED GUARANTY LTD的季度营收约是REPLIGEN CORP的1.4倍（$277.0M vs $197.9M），ASSURED GUARANTY LTD净利率更高（43.0% vs 6.7%，领先36.2%），ASSURED GUARANTY LTD同比增速更快（77.6% vs 13.6%），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 6.3%）
Assured Guaranty旗下的Assured Investment Management（AIM）是一家主打信贷策略的机构资产管理公司，2023年7月停止运营时管理资产规模约152亿美元，曾被二级投资者评为全球最知名的对冲基金之一。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
AGO vs RGEN — 直观对比
营收规模更大
AGO
是对方的1.4倍
$197.9M
营收增速更快
AGO
高出63.9%
13.6%
净利率更高
AGO
高出36.2%
6.7%
两年增速更快
RGEN
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $277.0M | $197.9M |
| 净利润 | $119.0M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 59.6% | 9.0% |
| 净利率 | 43.0% | 6.7% |
| 营收同比 | 77.6% | 13.6% |
| 净利润同比 | 561.1% | 143.9% |
| 每股收益（稀释后） | $2.56 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGORGEN
| Q4 25 | $277.0M | $197.9M | ||
| Q3 25 | $207.0M | $188.8M | ||
| Q2 25 | $281.0M | $182.4M | ||
| Q1 25 | $345.0M | $169.2M | ||
| Q4 24 | $156.0M | $174.1M | ||
| Q3 24 | $269.0M | $154.9M | ||
| Q2 24 | $202.0M | $154.1M | ||
| Q1 24 | $245.0M | $151.3M |
净利润AGORGEN
| Q4 25 | $119.0M | $13.3M | ||
| Q3 25 | $105.0M | $14.9M | ||
| Q2 25 | $103.0M | $14.9M | ||
| Q1 25 | $176.0M | $5.8M | ||
| Q4 24 | $18.0M | $-30.3M | ||
| Q3 24 | $171.0M | $-654.0K | ||
| Q2 24 | $78.0M | $3.3M | ||
| Q1 24 | $109.0M | $2.1M |
毛利率AGORGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率AGORGEN
| Q4 25 | 59.6% | 9.0% | ||
| Q3 25 | 65.2% | 8.9% | ||
| Q2 25 | 47.3% | 7.6% | ||
| Q1 25 | 66.4% | 3.9% | ||
| Q4 24 | 19.2% | -17.7% | ||
| Q3 24 | 81.8% | -5.1% | ||
| Q2 24 | 46.5% | 1.0% | ||
| Q1 24 | 58.8% | 1.3% |
净利率AGORGEN
| Q4 25 | 43.0% | 6.7% | ||
| Q3 25 | 50.7% | 7.9% | ||
| Q2 25 | 36.7% | 8.2% | ||
| Q1 25 | 51.0% | 3.4% | ||
| Q4 24 | 11.5% | -17.4% | ||
| Q3 24 | 63.6% | -0.4% | ||
| Q2 24 | 38.6% | 2.2% | ||
| Q1 24 | 44.5% | 1.4% |
每股收益（稀释后）AGORGEN
| Q4 25 | $2.56 | $0.24 | ||
| Q3 25 | $2.18 | $0.26 | ||
| Q2 25 | $2.08 | $0.26 | ||
| Q1 25 | $3.44 | $0.10 | ||
| Q4 24 | $0.40 | $-0.55 | ||
| Q3 24 | $3.17 | $-0.01 | ||
| Q2 24 | $1.41 | $0.06 | ||
| Q1 24 | $1.89 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $903.0M | $767.6M |
| 总债务越低越好 | $1.7B | $542.2M |
| 股东权益账面价值 | $5.7B | $2.1B |
| 总资产 | $12.2B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.30× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资AGORGEN
| Q4 25 | $903.0M | $767.6M | ||
| Q3 25 | $1.3B | $748.7M | ||
| Q2 25 | $939.0M | $708.9M | ||
| Q1 25 | $1.2B | $697.2M | ||
| Q4 24 | $1.2B | $757.4M | ||
| Q3 24 | $1.5B | $784.0M | ||
| Q2 24 | $1.7B | $809.1M | ||
| Q1 24 | $1.6B | $780.6M |
总债务AGORGEN
| Q4 25 | $1.7B | $542.2M | ||
| Q3 25 | $1.7B | $537.9M | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | $525.6M | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
股东权益AGORGEN
| Q4 25 | $5.7B | $2.1B | ||
| Q3 25 | $5.7B | $2.1B | ||
| Q2 25 | $5.6B | $2.1B | ||
| Q1 25 | $5.6B | $2.0B | ||
| Q4 24 | $5.5B | $2.0B | ||
| Q3 24 | $5.7B | $2.0B | ||
| Q2 24 | $5.5B | $2.0B | ||
| Q1 24 | $5.6B | $2.0B |
总资产AGORGEN
| Q4 25 | $12.2B | $2.9B | ||
| Q3 25 | $12.1B | $2.9B | ||
| Q2 25 | $12.1B | $2.9B | ||
| Q1 25 | $11.9B | $2.9B | ||
| Q4 24 | $11.9B | $2.8B | ||
| Q3 24 | $12.3B | $2.8B | ||
| Q2 24 | $12.1B | $2.9B | ||
| Q1 24 | $12.2B | $2.8B |
负债/权益比AGORGEN
| Q4 25 | 0.30× | 0.26× | ||
| Q3 25 | 0.30× | 0.26× | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.31× | 0.27× | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.30× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $259.0M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | 2.18× | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流AGORGEN
| Q4 25 | $259.0M | $25.7M | ||
| Q3 25 | $55.0M | $48.1M | ||
| Q2 25 | $78.0M | $28.6M | ||
| Q1 25 | $87.0M | $15.0M | ||
| Q4 24 | $47.0M | $39.2M | ||
| Q3 24 | $17.0M | $49.3M | ||
| Q2 24 | $58.0M | $42.2M | ||
| Q1 24 | $-74.0M | $44.7M |
自由现金流AGORGEN
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | — | $42.3M | ||
| Q2 24 | — | $37.4M | ||
| Q1 24 | — | $36.4M |
自由现金流率AGORGEN
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 27.3% | ||
| Q2 24 | — | 24.3% | ||
| Q1 24 | — | 24.0% |
资本支出强度AGORGEN
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 5.5% |
现金转化率AGORGEN
| Q4 25 | 2.18× | 1.93× | ||
| Q3 25 | 0.52× | 3.23× | ||
| Q2 25 | 0.76× | 1.92× | ||
| Q1 25 | 0.49× | 2.57× | ||
| Q4 24 | 2.61× | — | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.74× | 12.70× | ||
| Q1 24 | -0.68× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGO
| Insurance Segment | $226.0M | 82% |
| Other | $37.0M | 13% |
| Gain Loss On Investments Member1 | $8.0M | 3% |
| Non Credit Impairment Related Unrealized Fair Value Gains Losses On Credit Derivatives | $6.0M | 2% |
RGEN
暂无分部数据
